Welcome to our dedicated page for Stereotaxis Ord SEC filings (Ticker: STXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stereotaxis, Inc. filings document an operating medical-technology company focused on robotic systems and instruments for minimally invasive endovascular intervention. Recent Form 8-K reports record operating and financial results, product and regulatory information included in earnings materials, and material-event disclosures.
The company’s SEC record also includes a definitive proxy statement covering annual-meeting and shareholder voting matters, governance, executive compensation, and director elections. Capital-structure filings describe common stock, shelf registration use, and an at-the-market sales agreement for working capital, research and development, and commercialization of the company’s innovation pipeline.
Stereotaxis, Inc. provides an annual overview of its robotic magnetic navigation business, highlighting products for electrophysiology and complex endovascular procedures. The company reports system backlog of approximately $9.1 million as of December 31, 2025, compared with $14.4 million as of December 31, 2024, noting potential variability in converting backlog to revenue due to long sales and installation cycles.
The report emphasizes expansion of the portfolio, including the GenesisX RMN system, Synchrony and SynX lab solutions, and proprietary MAGiC and MAGiC Sweep catheters, alongside the 2024 acquisition of Access Point Technologies EP, Inc. It also discusses broad global regulatory clearances, a diversified recurring-revenue base from disposables and service, and detailed risk factors such as supply-chain pressures, reliance on strategic partners, capital-raising needs, and the scheduled end of Johnson & Johnson catheter supply obligations on December 31, 2025.
Stereotaxis, Inc. reported strong growth for 2025, with revenue rising to $32.4 million, up from $26.9 million, driven by new robotic systems and recurring disposables and service revenue. Fourth-quarter revenue reached $8.6 million, a 36% increase year over year.
Full-year gross margin was 53%, and adjusted operating loss improved to ($9.3) million from ($12.4) million. The company ended 2025 with $13.4 million in cash and no debt. Management highlighted regulatory approvals and initial commercialization of the GenesisX robot and MAGiC catheter portfolio, while acknowledging manufacturing ramp challenges.
For 2026, Stereotaxis expects double-digit revenue growth, with annual revenue projected to surpass $40 million and lower cash use. The company is targeting higher manufacturing volumes, at least five active GenesisX programs, over $3 million of Synchrony digital suite revenue, and progress across its endovascular robotics and AI-enabled digital solutions.
Stereotaxis, Inc. director Arun S. Menawat reported receiving a new equity award in the form of restricted share units of the company’s common stock. On 01/02/2026, he was granted 46,948 shares of common stock at a stated price of $0, increasing his directly held beneficial ownership to 992,457 shares after the transaction.
The filing explains that each restricted share unit represents the right to receive one share of common stock. These units vest on the earliest of three events: the fifth anniversary of the award date, the date his service as a director on the board ends, or the occurrence of a Change of Control as defined in the award documents.
Stereotaxis, Inc. director David Benfer reported an equity award of 46,948 shares of common stock on 01/02/2026. These were granted as restricted share units, each representing the right to receive one share of common stock at a price of $0 per share.
The restricted share units vest on the earliest of the fifth anniversary of the award date, the date his board service ends, or a Change of Control as defined in the award documents. After this grant, Benfer beneficially owns 515,872 shares directly, 2,700 shares indirectly through his spouse, and 210,255 shares indirectly through the Benfer Family Trust.
Stereotaxis, Inc. reported an equity award to one of its directors. On 01/02/2026, the director received a grant of 46,948 restricted share units, each representing a right to receive one share of Stereotaxis common stock. The transaction price is listed as $0, reflecting that this was an equity compensation grant rather than a market purchase.
After this award, the director beneficially owns 392,058 shares of common stock. The restricted share units vest on the earliest of the fifth anniversary of the award date, the date the director’s board service ends, or a defined Change of Control event. This filing is a routine disclosure of director compensation and ownership under insider reporting rules.
Stereotaxis, Inc. insider Nathan Fischel reported a new equity award. On 01/02/2026, he received 46,948 restricted share units of Stereotaxis common stock at a price of $0. Each unit represents one share of common stock.
The restricted share units vest on the earliest of the fifth anniversary of the award date, the end of his service on the board of directors, or a defined Change of Control. Following this grant, Fischel beneficially owns 677,672 shares directly.
He also has indirect beneficial ownership of 13,680,554 shares held by funds for which DAFNA Capital Management LLC serves as investment manager and general partner. Fischel is the Chief Executive Officer of DAFNA Capital Management LLC and is identified as both a director and a 10% owner of Stereotaxis.
Stereotaxis, Inc. reported an equity award to a company director. On 01/02/2026, the director received 46,948 shares of common stock as a grant of restricted share units at a stated price of $0 per share. Following this grant, the director beneficially owned 578,145 shares of Stereotaxis common stock in direct ownership.
The filing explains that each restricted share unit represents the right to receive one share of common stock. These units vest on the earliest of three events: the fifth anniversary of the award date, the date the director’s board service ends, or a defined Change of Control under the award documents. The report is signed by an attorney-in-fact for director Ross B. Levin, indicating this is routine insider equity compensation rather than a market sale.
Stereotaxis, Inc. director reports equity grant
A director of Stereotaxis, Inc. (STXS) reported receiving 46,948 shares of common stock on 01/02/2026 in a transaction valued at $0 per share. After this grant, the director beneficially owns 136,224 shares of Stereotaxis common stock in direct ownership.
The grant consists of restricted share units, each representing the right to receive one share of common stock. These units vest on the earliest of the fifth anniversary of the award date, the date the director’s service on the board ends, or a Change of Control as defined in the award documents.
Stereotaxis, Inc. (STXS) insider Paul J. Isaac reported open-market purchases of the company’s common stock. On 11/14/2025, an indirect account bought 20,000 shares at $2.24 per share, bringing indirect beneficial ownership to 2,786,557 shares held through Arbiter Partners Capital Management LLC and related managed accounts. On 11/17/2025, a direct account purchased 10,000 shares at $2.18 per share, resulting in 97,299 shares held directly. The filing explains that Arbiter is a registered investment adviser, that Isaac’s reported holdings include shares owned by an affiliated fund and managed accounts, and that he disclaims beneficial ownership except to the extent of his pecuniary interest.
The remarks note that Ross B. Levin, Arbiter’s Director of Research, serves on Stereotaxis’s board of directors and that this Form 4 is filed as a matter of caution without conceding that Isaac, Arbiter or the fund are statutory insiders.
Stereotaxis (STXS) reported Q3 2025 results. Revenue was $7.5 million, down from $9.2 million a year ago, as systems sales softened while disposables, service and accessories grew. Systems revenue was $1.9 million versus $4.4 million, and disposables, service and accessories reached $5.6 million versus $4.8 million.
Gross margin was $4.1 million, roughly flat year over year, while operating loss was $6.6 million versus $6.3 million. Net loss was $6.5 million compared with $6.2 million, and basic/diluted EPS was ($0.07) versus ($0.08). For the first nine months, revenue rose to $23.7 million from $20.6 million, reflecting stronger recurring revenue. Cash and cash equivalents were $10.5 million at September 30, 2025. Deferred revenue totaled $8.1 million, supporting future service and delivery obligations.
The company continued integrating Access Point Technologies (APT), which contributed $4.1 million in revenue for the nine months. Stereotaxis established a $50.0 million at‑the‑market program on August 29, 2025, with no shares issued under it through quarter-end. Shares outstanding were 93,324,763 as of October 31, 2025.